

Lluís Ballell

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3846124/publications.pdf>

Version: 2024-02-01

73
papers

3,168
citations

126858

33
h-index

168321

53
g-index

78
all docs

78
docs citations

78
times ranked

3931
citing authors

#	ARTICLE	IF	CITATIONS
1	Fueling Open-Source Drug Discovery: 177 Small-Molecule Leads against Tuberculosis. <i>ChemMedChem</i> , 2013, 8, 313-321.	1.6	277
2	Identification of Novel Imidazo[1,2-a]pyridine Inhibitors Targeting M. tuberculosis QcrB. <i>PLoS ONE</i> , 2012, 7, e52951.	1.1	162
3	New Small-Molecule Synthetic Antimycobacterials. <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 2153-2163.	1.4	159
4	Tetrahydropyrazolo[1,5-a]Pyrimidine-3-Carboxamide and N-Benzyl-6,7-Dihydrospiro[Piperidine-4,4-Thieno[3,2-c]Pyran] Analogues with Bactericidal Efficacy against <i>Mycobacterium tuberculosis</i> Targeting MmpL3. <i>PLoS ONE</i> , 2013, 8, e60933.	1.1	123
5	" β -Lactams against Tuberculosis – New Trick for an Old Dog?". <i>New England Journal of Medicine</i> , 2016, 375, 393-394.	13.9	111
6	Encoded Library Technology as a Source of Hits for the Discovery and Lead Optimization of a Potent and Selective Class of Bactericidal Direct Inhibitors of <i>Mycobacterium tuberculosis</i> InhA. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 1276-1288.	2.9	105
7	New thiopyrazolo[3,4-d]pyrimidine derivatives as anti-mycobacterial agents. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2007, 17, 1736-1740.	1.0	101
8	A new piperidinol derivative targeting mycolic acid transport in <i>Mycobacterium abscessus</i> . <i>Molecular Microbiology</i> , 2016, 101, 515-529.	1.2	100
9	Rapid Cytolysis of <i>Mycobacterium tuberculosis</i> by Faropenem, an Orally Bioavailable β -Lactam Antibiotic. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 1308-1319.	1.4	92
10	Improved BM212 MmpL3 Inhibitor Analogue Shows Efficacy in Acute Murine Model of Tuberculosis Infection. <i>PLoS ONE</i> , 2013, 8, e56980.	1.1	90
11	Essential but Not Vulnerable: Indazole Sulfonamides Targeting Inosine Monophosphate Dehydrogenase as Potential Leads against <i>Mycobacterium tuberculosis</i> . <i>ACS Infectious Diseases</i> , 2017, 3, 18-33.	1.8	77
12	Identification of KasA as the cellular target of an anti-tubercular scaffold. <i>Nature Communications</i> , 2016, 7, 12581.	5.8	72
13	Repurposing clinically approved cephalosporins for tuberculosis therapy. <i>Scientific Reports</i> , 2016, 6, 34293.	1.6	66
14	A New Chemical Probe for Proteomics of Carbohydrate-Binding Proteins. <i>ChemBioChem</i> , 2005, 6, 291-295.	1.3	63
15	Antitubercular drugs for an old target: GSK693 as a promising InhA direct inhibitor. <i>EBioMedicine</i> , 2016, 8, 291-301.	2.7	60
16	Design, Synthesis, and Evaluation of New Thiadiazole-Based Direct Inhibitors of Enoyl Acyl Carrier Protein Reductase (InhA) for the Treatment of Tuberculosis. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 613-624.	2.9	58
17	THPP target assignment reveals EchA6 as an essential fatty acid shuttle in mycobacteria. <i>Nature Microbiology</i> , 2016, 1, 15006.	5.9	57
18	Prioritizing multiple therapeutic targets in parallel using automated DNA-encoded library screening. <i>Nature Communications</i> , 2017, 8, 16081.	5.8	57

#	ARTICLE	IF	CITATIONS
19	A new chemical probe for the detection of the cancer-linked galectin-3. <i>Organic and Biomolecular Chemistry</i> , 2006, 4, 4387.	1.5	52
20	Testing Tuberculosis Drug Efficacy in a Zebrafish High-Throughput Translational Medicine Screen. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 753-762.	1.4	52
21	<i>Mycobacterium tuberculosis</i> Gyrase Inhibitors as a New Class of Antitubercular Drugs. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 1868-1875.	1.4	52
22	Whole Cell Target Engagement Identifies Novel Inhibitors of <i>Mycobacterium tuberculosis</i> Decaprenylphosphoryl- ¹² -ribose Oxidase. <i>ACS Infectious Diseases</i> , 2015, 1, 615-626.	1.8	51
23	Inhibiting mycobacterial tryptophan synthase by targeting the inter-subunit interface. <i>Scientific Reports</i> , 2017, 7, 9430.	1.6	48
24	Searching for New Leads for Tuberculosis: Design, Synthesis, and Biological Evaluation of Novel 2-Quinolin-4-yloxyacetamides. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 6709-6728.	2.9	41
25	A multitarget approach to drug discovery inhibiting <i>Mycobacterium tuberculosis</i> PyrG and Pank. <i>Scientific Reports</i> , 2018, 8, 3187.	1.6	41
26	Mycobacterial Dihydrofolate Reductase Inhibitors Identified Using Chemogenomic Methods and In Vitro Validation. <i>PLoS ONE</i> , 2015, 10, e0121492.	1.1	40
27	Novel insight into the reaction of nitro, nitroso and hydroxylamino benzothiazinones and of benzoxacinones with <i>Mycobacterium tuberculosis</i> DprE1. <i>Scientific Reports</i> , 2018, 8, 13473.	1.6	39
28	In vivo Enhancement in Bioavailability of Atazanavir in the Presence of Proton Pump Inhibitors using Mesoporous Materials. <i>ChemMedChem</i> , 2012, 7, 43-48.	1.6	38
29	Release of 50 new, drug-like compounds and their computational target predictions for open source anti-tubercular drug discovery. <i>PLoS ONE</i> , 2015, 10, e0142293.	1.1	38
30	Combinations of ¹² -Lactam Antibiotics Currently in Clinical Trials Are Efficacious in a DHP-I-Deficient Mouse Model of Tuberculosis Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 4997-4999.	1.4	37
31	Novel Pyrazole-Containing Compounds Active against <i>Mycobacterium tuberculosis</i> . <i>ACS Medicinal Chemistry Letters</i> , 2019, 10, 1423-1429.	1.3	37
32	Synthesis and Evaluation of New Thiodigalactoside-Based Chemical Probes to Label Galectin-3. <i>ChemBioChem</i> , 2009, 10, 1724-1733.	1.3	36
33	The antibiotic cyclomarin blocks arginine-phosphate-induced millisecond dynamics in the N-terminal domain of ClpC1 from <i>Mycobacterium tuberculosis</i> . <i>Journal of Biological Chemistry</i> , 2018, 293, 8379-8393.	1.6	36
34	A Phenotypic Based Target Screening Approach Delivers New Antitubercular CTP Synthetase Inhibitors. <i>ACS Infectious Diseases</i> , 2017, 3, 428-437.	1.8	34
35	High-Content Screening Technology Combined with a Human Granuloma Model as a New Approach To Evaluate the Activities of Drugs against <i>Mycobacterium tuberculosis</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 693-697.	1.4	33
36	Biochemical and Structural Characterization of Mycobacterial Aspartyl-tRNA Synthetase AspS, a Promising TB Drug Target. <i>PLoS ONE</i> , 2014, 9, e113568.	1.1	31

#	ARTICLE	IF	CITATIONS
37	Antimycobacterial drug discovery using Mycobacteria-infected amoebae identifies anti-infectives and new molecular targets. <i>Scientific Reports</i> , 2018, 8, 3939.	1.6	30
38	Identification and Profiling of Hydantoins—A Novel Class of Potent Antimycobacterial DprE1 Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 11221-11249.	2.9	30
39	Design, synthesis and structure-activity relationship study of wollamide B; a new potential anti TB agent. <i>PLoS ONE</i> , 2017, 12, e0176088.	1.1	30
40	Hydrolysis of Clavulanate by Mycobacterium tuberculosis β -Lactamase BlaC Harboring a Canonical SDN Motif. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 5714-5720.	1.4	28
41	<i>N</i> -Benzyl- α -(heteroaryl)methylbenzamides: A New Class of Direct NADH-Dependent <i>trans</i> -Enoyl- β -Acyl Carrier Protein Reductase (InhA) Inhibitors with Antitubercular Activity. <i>ChemMedChem</i> , 2016, 11, 687-701.	1.6	28
42	Microwave-assisted, tin-mediated, regioselective 3-O-alkylation of galactosides. <i>Tetrahedron Letters</i> , 2004, 45, 6685-6687.	0.7	27
43	Large pore mesoporous silica induced weight loss in obese mice. <i>Nanomedicine</i> , 2014, 9, 1353-1362.	1.7	27
44	<i>In vivo</i> oral toxicological evaluation of mesoporous silica particles. <i>Nanomedicine</i> , 2013, 8, 57-64.	1.7	24
45	Synthesis and evaluation of mimetics of UDP and UDP- β -d-galactose, dTDP and dTDP- β -d-glucose with monosaccharides replacing the key pyrophosphate unit. <i>Organic and Biomolecular Chemistry</i> , 2005, 3, 1109-1115.	1.5	22
46	Novel inhibitors of Mycobacterium tuberculosis GuaB2 identified by a target based high-throughput phenotypic screen. <i>Scientific Reports</i> , 2016, 6, 38986.	1.6	22
47	Novel Antitubercular 6-Dialkylaminopyrimidine Carboxamides from Phenotypic Whole-Cell High Throughput Screening of a SoftFocus Library: Structure-Activity Relationship and Target Identification Studies. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 10118-10134.	2.9	22
48	Target Identification of Mycobacterium tuberculosis Phenotypic Hits Using a Concerted Chemogenomic, Biophysical, and Structural Approach. <i>Frontiers in Pharmacology</i> , 2017, 8, 681.	1.6	22
49	<i>In vivo</i> potent BM635 analogue with improved drug-like properties. <i>European Journal of Medicinal Chemistry</i> , 2018, 145, 539-550.	2.6	22
50	Encapsulation of Anti-Tuberculosis Drugs within Mesoporous Silica and Intracellular Antibacterial Activities. <i>Nanomaterials</i> , 2014, 4, 813-826.	1.9	21
51	A Focused Screen Identifies Antifolates with Activity on Mycobacterium tuberculosis. <i>ACS Infectious Diseases</i> , 2015, 1, 604-614.	1.8	21
52	New direct inhibitors of InhA with antimycobacterial activity based on a tetrahydropyran scaffold. <i>European Journal of Medicinal Chemistry</i> , 2016, 112, 252-257.	2.6	20
53	Identification and characterization of aspartyl-tRNA synthetase inhibitors against Mycobacterium tuberculosis by an integrated whole-cell target-based approach. <i>Scientific Reports</i> , 2018, 8, 12664.	1.6	20
54	Optimization of Hydantoins as Potent Antimycobacterial Decaprenylphosphoryl- β -Ribose Oxidase (DprE1) Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 5367-5386.	2.9	18

#	ARTICLE	IF	CITATIONS
55	4-Substituted Thioquinolines and Thiazoloquinolines: Potent, Selective, and Tween-80 in-vitro Dependent Families of Antitubercular Agents with Moderate in-vivo Activity. <i>ChemMedChem</i> , 2011, 6, 2252-2263.	1.6	17
56	Carbamoyl Triazoles, Known Serine Protease Inhibitors, Are a Potent New Class of Antimalarials. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 6448-6455.	2.9	17
57	Accelerating Early Antituberculosis Drug Discovery by Creating Mycobacterial Indicator Strains That Predict Mode of Action. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	15
58	A Developability-Focused Optimization Approach Allows Identification of in Vivo Fast-Acting Antimalarials: N-[3-[(Benzimidazol-2-yl)amino]propyl]amides. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 4573-4580.	2.9	12
59	MymA Bioactivated Thioalkylbenzoxazole Prodrug Family Active against <i>Mycobacterium tuberculosis</i> . <i>Journal of Medicinal Chemistry</i> , 2020, 63, 4732-4748.	2.9	12
60	Discovery of novel InhA reductase inhibitors: application of pharmacophore- and shape-based screening approach. <i>Future Medicinal Chemistry</i> , 2013, 5, 249-259.	1.1	11
61	Open Lab as a source of hits and leads against tuberculosis, malaria and kinetoplastid diseases. <i>Nature Reviews Drug Discovery</i> , 2016, 15, 292-292.	21.5	10
62	Pharmaceutical salt of BM635 with improved bioavailability. <i>European Journal of Pharmaceutical Sciences</i> , 2017, 99, 17-23.	1.9	10
63	An open toolkit for tracking open science partnership implementation and impact. <i>Gates Open Research</i> , 2019, 3, 1442.	2.0	10
64	The small-molecule SMART751 reverses <i>Mycobacterium tuberculosis</i> resistance to ethionamide in acute and chronic mouse models of tuberculosis. <i>Science Translational Medicine</i> , 2022, 14, eaaz6280.	5.8	10
65	Repurposing Infectious Disease Hits as Anti- <i>Cryptosporidium</i> Leads. <i>ACS Infectious Diseases</i> , 2021, 7, 1275-1282.	1.8	8
66	Non-absorbable mesoporous silica for the development of protein sequestration therapies. <i>Biochemical and Biophysical Research Communications</i> , 2015, 468, 428-434.	1.0	7
67	Fighting Shigella by Blocking Its Disease-Causing Toxin. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 6059-6069.	2.9	7
68	Tebipenem as an oral alternative for the treatment of typhoid caused by XDR <i>Salmonella</i> Typhi. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 3197-3200.	1.3	7
69	The repurposing of Tebipenem pivoxil as alternative therapy for severe gastrointestinal infections caused by extensively drug-resistant Shigella spp. <i>ELife</i> , 2022, 11, .	2.8	6
70	Synthesis, antimycobacterial activity and influence on mycobacterial InhA and PknB of 12-membered cyclopeptide. <i>Bioorganic and Medicinal Chemistry</i> , 2018, 26, 3166-3190.	1.4	2
71	Tres Cantos Open Lab: celebrating a decade of innovation in collaboration to combat endemic infectious diseases. <i>Nature Reviews Drug Discovery</i> , 2021, 20, 799-800.	21.5	2
72	An open toolkit for tracking open science partnership implementation and impact. <i>Gates Open Research</i> , 0, 3, 1442.	2.0	2

#	ARTICLE	IF	CITATIONS
73	Amino alditols as inhibitors of mycobacterial cell wall biosynthesis. Biochemical Society Transactions, 2002, 30, A27-A27.	1.6	0